Une expérience reconnue en développement pharmaceutique. Une intégration permanente de technologies innovantes et des extensions de capacités.
CENTRES DE COMPETENCES
ClaireDUBOIS BERGERSecrétaire Générale Ecole de Commerce (ESCP)
Claire has a senior experience in supporting groups growth in integrating new activities and business acquisitions. Her background and skills cover controlling & accounting, project financing, IT, legal and management of support services. Claire will focus on IT including the ERP and integration of subsidiaries, structuring the core system while preserving agility and identity of each entity.
FrédéricGAUSSENSDirecteur Développement Commercial & Stratégie Master en Finance
Frédéric a plus de 10 ans d’expérience dans le secteur de la prestation de services en Sciences de la Vie, au travers de plusieurs postes en finances, marketing, stratégie et développement commercial, au sein de plusieurs entreprises internationales. Frédéric est en charge des initiatives stratégiques pour accompagner l’expansion internationale d’Amatsigroup :croissance, fusions-acquisitions, alliances, partenariats et développement institutionnel.
YvesGONNISSENManaging Director PhD en ingénierie Biochimique
Yves has 15 years of experience in pharmaceutical product development. He holds a Master’s degree in Biochemical Engineering. He obtained his PhD at Ghent University in Belgium where he pursued his research interests in the fields of pharmaceutical technology and pharmaceutical drug product development. In 2002 he started his professional career at Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). In 2007 he founded SEPS Pharma specialized in drug product development. In 2015, Amatsigroup acquired his company. Ever since, he has managed Amatsigroup services in formulation development & manufacturing focusing on innovative technologies especially for bioavailiability enhancement or oral controlled release.
Amatsigroup achieved the process transfer of our injectable drug from a major industrial manufacturer and successfully managed the critical step of lyophilization. Amatsigroup has demonstrated its high adaptability to the manufacture of small batches suitable for the orphan drug market. To accommodate our expansion on the Japanese market, Amatsigroup’s team was very reactive and involved and got the Japanese PDMA accreditation within the expected timeframe.
Christophe Pasik, CEO
Keocyt SAS, A Riemser Group company
Amatsigroup is a very expertise based and science driven company focussing on the priorities of the sponsor/client. Over the last five to six years they evolved to a well-balanced group of highly experienced, flexible and self-driving teams, invested in premises and equipment allowing them to cope with standard and specialty project requirements in the formulation and analytical domain for pre-clinical and clinical needs.
John Oliver, Head CMC Development
Major biotech company